Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers
NCT ID: NCT00389792
Last Updated: 2009-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
72 participants
INTERVENTIONAL
2006-07-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden
NCT01356914
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
NCT00971204
Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation
NCT00224341
His-pacing and AV-node Ablation vs. Pulmonary Vein Isolation for Atrial Fibrillation
NCT04512586
AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
NCT00589303
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants.)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ATI-2042 200 mg
ATI-2042
no intervention
ATI-2042 200 mg
To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
ATI-2042 400 mg
ATI-2042
no intervention
ATI-2042 200 mg
To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
ATI-2042 600 mg
ATI-2042
no intervention
ATI-2042 200 mg
To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
ATI-2042 Placebo
ATI-2042
no intervention
ATI-2042 200 mg
To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATI-2042
no intervention
ATI-2042 200 mg
To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pacemaker with appropriate AF diagnostics and recording capabilities
Exclusion Criteria
* Cardioversion within one month of screening
* Severe left ventricular dysfunction or CHF with NYHA Class III or above
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARYx Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ARYx Therapeutics, 6300 Dumbarton Circle, Fremont, CA 94555
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Ezekowitz, MBChB, PhD
Role: STUDY_CHAIR
Main Line Health
Olga Bandman, MD
Role: STUDY_DIRECTOR
ARYx Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ARYx Investigational Site
Phoenix, Arizona, United States
ARYx Investigational Site
Scottsdale, Arizona, United States
ARYx Investigational Site
Tucson, Arizona, United States
ARYx Investigational Site
Larkspur, California, United States
ARYx Investigational Site
Aurora, Colorado, United States
ARYx Investigational Site
Hollywood, Florida, United States
ARYx Investigational Site
Jacksonville Beach, Florida, United States
ARYx Investigational Site
Atlanta, Georgia, United States
ARYx Investigational Site
Marietta, Georgia, United States
ARYx Investigational Site
Chicago, Illinois, United States
ARYx Investigational Site
Towson, Maryland, United States
ARYx Investigational Site
Saginaw, Michigan, United States
ARYx Investigational Site
Minneapolis, Minnesota, United States
ARYx Investigational Site
St Louis, Missouri, United States
ARYx Investigational Site
Lincoln, Nebraska, United States
ARYx Investigational Site
Warren Township, New Jersey, United States
ARYx Investigational Site
Albuquerque, New Mexico, United States
ARYx Investigational Site
Buffalo, New York, United States
ARYx Investigational Site
Hershey, Pennsylvania, United States
ARYx Investigational Site
Wynnewood, Pennsylvania, United States
ARYx Investigational Site
Charleston, South Carolina, United States
ARYx Investigational Site
Nashville, Tennessee, United States
ARYx Investigational Site
Austin, Texas, United States
ARYx Investigational Site
Houston, Texas, United States
ARYx Investigational Site
Burlington, Vermont, United States
ARYx Investigational Site
Newport News, Virginia, United States
ARYx Investigational Site
Charleston, West Virginia, United States
ARYx Investigational Site
Edmonton, Alberta, Canada
ARYx Investigational Site
Edmonton, Alberta, Canada
ARYx Investigational Site
Campbell River, British Columbia, Canada
ARYx Investigational Site
Vancouver, British Columbia, Canada
ARYx Investigational Site
Victoria, British Columbia, Canada
ARYx Investigational Site
London, Ontario, Canada
ARYx Investigational Site
Niagara Falls, Ontario, Canada
ARYx Investigational Site
Ottawa, Ontario, Canada
ARYx Investigational Site
Montreal, Quebec, Canada
ARYx Investigational Site
Montreal, Quebec, Canada
ARYx Investigational Sites
Montreal, Quebec, Canada
ARYx Investigational Site
Sherbrooke, Quebec, Canada
ARYx Investigational Site
Terrebonne, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATI 2042-CLN 205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.